MoonLake Immunotherapeutics Reports Strong VELA Trial Results for Sonelokimab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Yahoo Finance
- Clinical Trial Results: At Week 52 of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100 with sonelokimab, demonstrating its superior efficacy in treating moderate-to-severe hidradenitis suppurativa compared to competitors.
- Quality of Life Improvement: Patients reported a mean improvement of 15.0 points in HS-specific quality of life scores (HiSQOL) at Week 52, indicating a shift from 'severe' to 'mild' impairment, which not only enhances patient satisfaction but also strengthens the company's competitive position in the market.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming the long-term safety of sonelokimab, which supports its future marketability and acceptance among healthcare providers.
- Future Plans: MoonLake plans to submit a Biologics License Application (BLA) by the end of September 2026 and will hold an Investor Day webcast on June 22, 2026, to discuss these findings and outline its commercialization strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise
12 Analyst Rating
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 19.210
Low
5.00
Averages
24.10
High
45.00
Current: 19.210
Low
5.00
Averages
24.10
High
45.00
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results for Sonelokimab
- Clinical Trial Results: MoonLake Immunotherapeutics announced that in its Phase 3 VELA-1 and VELA-2 trials, 67.2% of patients treated with Sonelokimab achieved HiSCR75 at Week 52, indicating significant efficacy in treating moderate-to-severe hidradenitis suppurativa, which could enhance the company's market share in this area.
- Consistent Safety Profile: The safety profile of Sonelokimab in the VELA clinical programs remained stable over time with no new safety signals detected, providing confidence for future regulatory approvals and potentially accelerating the FDA review process.
- Upcoming Milestones: The company expects to submit a Biologics License Application (BLA) for Sonelokimab by the end of September 2026, and plans to release primary endpoint data from the Phase 3 IZAR-2 trial in PsA in the second half of 2026, laying the groundwork for future product line expansion.
- Investor Day Event: MoonLake is hosting an investor day webcast today to discuss clinical data and guidance on upcoming events, which is expected to attract investor interest and further enhance the company's image in the capital markets.
See More
MoonLake Immunotherapeutics Raises $150 Million in Public Offering
- Funding Size: MoonLake Immunotherapeutics announced a $150 million public offering, intending to raise funds through the issuance of Class A ordinary shares and pre-funded warrants, aimed at supporting its key R&D projects.
- Use of Proceeds: The net proceeds from this offering will be allocated to the research, development, and pre-commercialization of its lead investigational 40-kDa humanized nanobody, Sonelokimab, as well as for general corporate purposes, indicating the company's commitment to future product launches.
- Clinical Progress: The company has made significant strides in clinical trials for Sonelokimab targeting Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA), particularly with positive 52-week results from the VELA-1 and VELA-2 trials demonstrating promising efficacy.
- Market Performance: MLTX stock has traded between $5.95 and $62.75 over the past year, closing at $22.16 on Monday with a 15.36% increase, although it dipped 2.53% in after-hours trading, reflecting overall market recognition of its future potential.
See More
MoonLake Immunotherapeutics Proposes $150M Public Offering
- Public Offering Plan: MoonLake Immunotherapeutics has proposed a public offering of $150 million in Class A ordinary shares, along with pre-funded warrants for certain investors, which is expected to provide substantial funding to support research and commercialization activities.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in Class A ordinary shares, allowing flexibility to adjust the financing scale based on market demand.
- Clear Use of Proceeds: The net proceeds will primarily support the development of Sonelokimab, MoonLake's lead drug candidate, which could present significant market opportunities if regulatory approval is obtained, while remaining funds will be allocated to general corporate purposes to ensure operational stability.
- Market Reaction: Following the announcement of the public offering, MLTX shares fell 3.4% in after-hours trading, reflecting a cautious market sentiment regarding the financing plan, which may impact investor confidence in the company's future growth.
See More
MoonLake Immunotherapeutics Shares Surge 15% on Positive Trial Results
- Clinical Trial Results: MoonLake's final Week 52 results indicate that approximately two-thirds of patients achieved at least a 75% reduction in painful abscesses and nodules, with one-third achieving complete clearance, suggesting significant efficacy that could reshape market dynamics.
- FDA Application Plans: The company plans to submit its biologics license application to the FDA by the end of September, expected to include data from both adults and adolescents, which could expedite the drug's market entry and enhance the company's competitive edge.
- Surge in Investor Sentiment: Retail investor sentiment around MLTX surged from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume significantly increasing, reflecting strong market confidence in the company's growth potential, with expectations of a $5 billion market cap increase by year-end.
- Optimistic Analyst Ratings: According to Koyfin, 11 out of 15 analysts covering MLTX rate it 'Buy' or higher, with a 12-month average price target of $27.62, representing about a 25% upside from the current stock price, indicating a positive outlook for its future performance.
See More
Middle East Tensions Ease Amid New China Trade Restrictions
- Middle East Peace Progress: A joint statement from Qatar and Pakistan indicates that the U.S. and Iran have agreed to a 60-day roadmap for peace, which, while easing tensions, leaves investors cautious about the potential impacts on market stability.
- Escalating Trade Restrictions: China has implemented strict dual-use export controls targeting specific U.S. defense, technology, and rare earth companies, which could pose significant operational challenges for these firms and affect overall market sentiment.
- Mixed U.S. Stock Futures: Following the Juneteenth holiday, U.S. stock futures showed mixed results, with Nasdaq futures flat while S&P 500 and Dow futures fell by 0.1% and 0.3% respectively, reflecting market caution ahead of key economic data releases.
- Earnings Reports in Focus: Investors are closely watching for upcoming earnings reports from Micron Technology and the core Personal Consumption Expenditures data, which are expected to provide critical insights into the Federal Reserve's rate direction and influence market trends.
See More
US-Iran Negotiations and Market Reactions
- US-Iran Negotiation Progress: US Vice President J.D. Vance met with Iranian officials in Switzerland to discuss strategies for maintaining the ceasefire, amidst a backdrop where 65% of Americans disapprove of President Trump's handling of Iran, potentially impacting future negotiations.
- Market Sentiment Volatility: Market sentiment weakened as Iran restricted traffic through the Strait of Hormuz, leading to a 0.12% drop in Dow futures, a 0.21% decline in S&P 500 futures, and a 0.22% decrease in Nasdaq 100 futures, reflecting investor concerns over the situation.
- Oil Price Increase: Amid escalating tensions, Brent crude futures rose to around $80.25 per barrel, while WTI crude futures climbed 1.20% to approximately $77.52 per barrel, indicating market worries about potential supply disruptions.
- Economic Data Focus: Markets will closely watch May's core Personal Consumption Expenditures data, the Fed's preferred inflation gauge, especially after the Fed kept interest rates unchanged, with expectations of a rate hike in 2026 that could influence future market trends.
See More
MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results for Sonelokimab
- Clinical Trial Results: MoonLake Immunotherapeutics announced that in its Phase 3 VELA-1 and VELA-2 trials, 67.2% of patients treated with Sonelokimab achieved HiSCR75 at Week 52, indicating significant efficacy in treating moderate-to-severe hidradenitis suppurativa, which could enhance the company's market share in this area.
- Consistent Safety Profile: The safety profile of Sonelokimab in the VELA clinical programs remained stable over time with no new safety signals detected, providing confidence for future regulatory approvals and potentially accelerating the FDA review process.
- Upcoming Milestones: The company expects to submit a Biologics License Application (BLA) for Sonelokimab by the end of September 2026, and plans to release primary endpoint data from the Phase 3 IZAR-2 trial in PsA in the second half of 2026, laying the groundwork for future product line expansion.
- Investor Day Event: MoonLake is hosting an investor day webcast today to discuss clinical data and guidance on upcoming events, which is expected to attract investor interest and further enhance the company's image in the capital markets.
See More
MoonLake Immunotherapeutics Raises $150 Million in Public Offering
- Funding Size: MoonLake Immunotherapeutics announced a $150 million public offering, intending to raise funds through the issuance of Class A ordinary shares and pre-funded warrants, aimed at supporting its key R&D projects.
- Use of Proceeds: The net proceeds from this offering will be allocated to the research, development, and pre-commercialization of its lead investigational 40-kDa humanized nanobody, Sonelokimab, as well as for general corporate purposes, indicating the company's commitment to future product launches.
- Clinical Progress: The company has made significant strides in clinical trials for Sonelokimab targeting Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA), particularly with positive 52-week results from the VELA-1 and VELA-2 trials demonstrating promising efficacy.
- Market Performance: MLTX stock has traded between $5.95 and $62.75 over the past year, closing at $22.16 on Monday with a 15.36% increase, although it dipped 2.53% in after-hours trading, reflecting overall market recognition of its future potential.
See More
MoonLake Immunotherapeutics Proposes $150M Public Offering
- Public Offering Plan: MoonLake Immunotherapeutics has proposed a public offering of $150 million in Class A ordinary shares, along with pre-funded warrants for certain investors, which is expected to provide substantial funding to support research and commercialization activities.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in Class A ordinary shares, allowing flexibility to adjust the financing scale based on market demand.
- Clear Use of Proceeds: The net proceeds will primarily support the development of Sonelokimab, MoonLake's lead drug candidate, which could present significant market opportunities if regulatory approval is obtained, while remaining funds will be allocated to general corporate purposes to ensure operational stability.
- Market Reaction: Following the announcement of the public offering, MLTX shares fell 3.4% in after-hours trading, reflecting a cautious market sentiment regarding the financing plan, which may impact investor confidence in the company's future growth.
See More
MoonLake Immunotherapeutics Shares Surge 15% on Positive Trial Results
- Clinical Trial Results: MoonLake's final Week 52 results indicate that approximately two-thirds of patients achieved at least a 75% reduction in painful abscesses and nodules, with one-third achieving complete clearance, suggesting significant efficacy that could reshape market dynamics.
- FDA Application Plans: The company plans to submit its biologics license application to the FDA by the end of September, expected to include data from both adults and adolescents, which could expedite the drug's market entry and enhance the company's competitive edge.
- Surge in Investor Sentiment: Retail investor sentiment around MLTX surged from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume significantly increasing, reflecting strong market confidence in the company's growth potential, with expectations of a $5 billion market cap increase by year-end.
- Optimistic Analyst Ratings: According to Koyfin, 11 out of 15 analysts covering MLTX rate it 'Buy' or higher, with a 12-month average price target of $27.62, representing about a 25% upside from the current stock price, indicating a positive outlook for its future performance.
See More
Middle East Tensions Ease Amid New China Trade Restrictions
- Middle East Peace Progress: A joint statement from Qatar and Pakistan indicates that the U.S. and Iran have agreed to a 60-day roadmap for peace, which, while easing tensions, leaves investors cautious about the potential impacts on market stability.
- Escalating Trade Restrictions: China has implemented strict dual-use export controls targeting specific U.S. defense, technology, and rare earth companies, which could pose significant operational challenges for these firms and affect overall market sentiment.
- Mixed U.S. Stock Futures: Following the Juneteenth holiday, U.S. stock futures showed mixed results, with Nasdaq futures flat while S&P 500 and Dow futures fell by 0.1% and 0.3% respectively, reflecting market caution ahead of key economic data releases.
- Earnings Reports in Focus: Investors are closely watching for upcoming earnings reports from Micron Technology and the core Personal Consumption Expenditures data, which are expected to provide critical insights into the Federal Reserve's rate direction and influence market trends.
See More
US-Iran Negotiations and Market Reactions
- US-Iran Negotiation Progress: US Vice President J.D. Vance met with Iranian officials in Switzerland to discuss strategies for maintaining the ceasefire, amidst a backdrop where 65% of Americans disapprove of President Trump's handling of Iran, potentially impacting future negotiations.
- Market Sentiment Volatility: Market sentiment weakened as Iran restricted traffic through the Strait of Hormuz, leading to a 0.12% drop in Dow futures, a 0.21% decline in S&P 500 futures, and a 0.22% decrease in Nasdaq 100 futures, reflecting investor concerns over the situation.
- Oil Price Increase: Amid escalating tensions, Brent crude futures rose to around $80.25 per barrel, while WTI crude futures climbed 1.20% to approximately $77.52 per barrel, indicating market worries about potential supply disruptions.
- Economic Data Focus: Markets will closely watch May's core Personal Consumption Expenditures data, the Fed's preferred inflation gauge, especially after the Fed kept interest rates unchanged, with expectations of a rate hike in 2026 that could influence future market trends.
See More
